ABCL Heads Into Earnings With Shorts Dug In and Analysts Warming Up
AbCellera Biologics reports Monday with an unusually charged setup: 15% short interest, a stock that just surged 21% in a week, and two analyst target raises filed the morning after the last quarterly print. Short…